Cargando…

A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity

Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, invasion, and other cancer hallmarks. The goal of precision medicine is to identify therapeutically-actionable mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Laderas, Ted G., Heiser, Laura M., Sönmez, Kemal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688377/
https://www.ncbi.nlm.nih.gov/pubmed/26779250
http://dx.doi.org/10.3389/fgene.2015.00341
_version_ 1782406729333473280
author Laderas, Ted G.
Heiser, Laura M.
Sönmez, Kemal
author_facet Laderas, Ted G.
Heiser, Laura M.
Sönmez, Kemal
author_sort Laderas, Ted G.
collection PubMed
description Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, invasion, and other cancer hallmarks. The goal of precision medicine is to identify therapeutically-actionable mutations from large-scale omic datasets. However, the multiplicity of oncogenes required for transformation, known as oncogenic collaboration, makes assigning effective treatments difficult. Motivated by this observation, we propose a new type of oncogenic collaboration where mutations in genes that interact with an oncogene may contribute to the oncogene’s deleterious potential, a new genomic feature that we term “surrogate oncogenes.” Surrogate oncogenes are representatives of these mutated subnetworks that interact with oncogenes. By mapping mutations to a protein–protein interaction network, we determine the significance of the observed distribution using permutation-based methods. For a panel of 38 breast cancer cell lines, we identified a significant number of surrogate oncogenes in known oncogenes such as BRCA1 and ESR1, lending credence to this approach. In addition, using Random Forest Classifiers, we show that these significant surrogate oncogenes predict drug sensitivity for 74 drugs in the breast cancer cell lines with a mean error rate of 30.9%. Additionally, we show that surrogate oncogenes are predictive of survival in patients. The surrogate oncogene framework incorporates unique or rare mutations from a single sample, and therefore has the potential to integrate patient-unique mutations into drug sensitivity predictions, suggesting a new direction in precision medicine and drug development. Additionally, we show the prevalence of significant surrogate oncogenes in multiple cancers from The Cancer Genome Atlas, suggesting that surrogate oncogenes may be a useful genomic feature for guiding pancancer analyses and assigning therapies across many tissue types.
format Online
Article
Text
id pubmed-4688377
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46883772016-01-15 A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity Laderas, Ted G. Heiser, Laura M. Sönmez, Kemal Front Genet Genetics Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, invasion, and other cancer hallmarks. The goal of precision medicine is to identify therapeutically-actionable mutations from large-scale omic datasets. However, the multiplicity of oncogenes required for transformation, known as oncogenic collaboration, makes assigning effective treatments difficult. Motivated by this observation, we propose a new type of oncogenic collaboration where mutations in genes that interact with an oncogene may contribute to the oncogene’s deleterious potential, a new genomic feature that we term “surrogate oncogenes.” Surrogate oncogenes are representatives of these mutated subnetworks that interact with oncogenes. By mapping mutations to a protein–protein interaction network, we determine the significance of the observed distribution using permutation-based methods. For a panel of 38 breast cancer cell lines, we identified a significant number of surrogate oncogenes in known oncogenes such as BRCA1 and ESR1, lending credence to this approach. In addition, using Random Forest Classifiers, we show that these significant surrogate oncogenes predict drug sensitivity for 74 drugs in the breast cancer cell lines with a mean error rate of 30.9%. Additionally, we show that surrogate oncogenes are predictive of survival in patients. The surrogate oncogene framework incorporates unique or rare mutations from a single sample, and therefore has the potential to integrate patient-unique mutations into drug sensitivity predictions, suggesting a new direction in precision medicine and drug development. Additionally, we show the prevalence of significant surrogate oncogenes in multiple cancers from The Cancer Genome Atlas, suggesting that surrogate oncogenes may be a useful genomic feature for guiding pancancer analyses and assigning therapies across many tissue types. Frontiers Media S.A. 2015-12-23 /pmc/articles/PMC4688377/ /pubmed/26779250 http://dx.doi.org/10.3389/fgene.2015.00341 Text en Copyright © 2015 Laderas, Heiser and Sönmez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Laderas, Ted G.
Heiser, Laura M.
Sönmez, Kemal
A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title_full A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title_fullStr A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title_full_unstemmed A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title_short A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
title_sort network-based model of oncogenic collaboration for prediction of drug sensitivity
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688377/
https://www.ncbi.nlm.nih.gov/pubmed/26779250
http://dx.doi.org/10.3389/fgene.2015.00341
work_keys_str_mv AT laderastedg anetworkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity
AT heiserlauram anetworkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity
AT sonmezkemal anetworkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity
AT laderastedg networkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity
AT heiserlauram networkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity
AT sonmezkemal networkbasedmodelofoncogeniccollaborationforpredictionofdrugsensitivity